Lexicon Pharmaceuticals Reports 3rd Quarter Financial Results And Discusses Collaboration With Sanofi For Sotagliflozin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Lexicon Pharma (LXRX) Tops Q3 EPS by 2c
November 6, 2015 9:15 AM ESTLexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.34), $0.02 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $566 thousand versus the consensus estimate of $370 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
... MoreSanofi (SNY), Lexicon Pharma (LXRX) Enter Sotagliflozin Commercialization, Development Agreement
November 6, 2015 6:26 AM ESTSanofi (NYSE: SNY) and Lexicon Pharma (Nasdaq: LXRX) announced that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
"This agreement with Lexicon reinforces our commitment to helping people living with diabetes," said Pascale Witz, Executive Vice President, Sanofi, who will lead the Global Diabetes and Cardiovascular Care Business Unit in the company's new organizational structure. "Adding... More
